BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34446801)

  • 21. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
    Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
    Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexamethasone nanowafer as an effective therapy for dry eye disease.
    Coursey TG; Henriksson JT; Marcano DC; Shin CS; Isenhart LC; Ahmed F; De Paiva CS; Pflugfelder SC; Acharya G
    J Control Release; 2015 Sep; 213():168-174. PubMed ID: 26184051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. pH sensitive dexamethasone encapsulated laponite nanoplatelets: Release mechanism and cytotoxicity.
    Roozbahani M; Kharaziha M; Emadi R
    Int J Pharm; 2017 Feb; 518(1-2):312-319. PubMed ID: 28062364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Supramolecular nanofibers of dexamethasone derivatives to form hydrogel for topical ocular drug delivery.
    Zhang Z; Yu J; Zhou Y; Zhang R; Song Q; Lei L; Li X
    Colloids Surf B Biointerfaces; 2018 Apr; 164():436-443. PubMed ID: 29438842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL.
    Vallance K; Liu W; Mandrell BN; Panetta JC; Gattuso JS; Hockenberry M; Zupanec S; Yang L; Yang J; Hinds PS
    Eur J Cancer; 2010 Jul; 46(10):1848-55. PubMed ID: 20400291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Employing Macrophage-Derived Microvesicle for Kidney-Targeted Delivery of Dexamethasone: An Efficient Therapeutic Strategy against Renal Inflammation and Fibrosis.
    Tang TT; Lv LL; Wang B; Cao JY; Feng Y; Li ZL; Wu M; Wang FM; Wen Y; Zhou LT; Ni HF; Chen PS; Gu N; Crowley SD; Liu BC
    Theranostics; 2019; 9(16):4740-4755. PubMed ID: 31367254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcorneal iontophoresis of dendrimers: PAMAM corneal penetration and dexamethasone delivery.
    Souza JG; Dias K; Silva SA; de Rezende LC; Rocha EM; Emery FS; Lopez RF
    J Control Release; 2015 Feb; 200():115-24. PubMed ID: 25553828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
    Roderick JE; Gallagher KM; Murphy LC; O'Connor KW; Tang K; Zhang B; Brehm MA; Greiner DL; Yu J; Zhu LJ; Green MR; Kelliher MA
    Blood; 2021 Jan; 137(4):500-512. PubMed ID: 33507291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The synergistic effect of nano-hydroxyapatite and dexamethasone in the fibrous delivery system of gelatin and poly(l-lactide) on the osteogenesis of mesenchymal stem cells.
    Amjadian S; Seyedjafari E; Zeynali B; Shabani I
    Int J Pharm; 2016 Jun; 507(1-2):1-11. PubMed ID: 27107902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.
    Wandler AM; Huang BJ; Craig JW; Hayes K; Yan H; Meyer LK; Scacchetti A; Monsalve G; Dail M; Li Q; Wong JC; Weinberg O; Hasserjian RP; Kogan SC; Jonsson P; Yamamoto K; Sampath D; Nakitandwe J; Downing JR; Zhang J; Aster JC; Taylor BS; Shannon K
    Leukemia; 2020 Aug; 34(8):2025-2037. PubMed ID: 32066867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.
    Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM
    Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone-loaded Polymeric Nanoconstructs for Monitoring and Treating Inflammatory Bowel Disease.
    Lee A; De Mei C; Fereira M; Marotta R; Yoon HY; Kim K; Kwon IC; Decuzzi P
    Theranostics; 2017; 7(15):3653-3666. PubMed ID: 29109767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
    Bamezai S; Demir D; Pulikkottil AJ; Ciccarone F; Fischbein E; Sinha A; Borga C; Te Kronnie G; Meyer LH; Mohr F; Götze M; Caiafa P; Debatin KM; Döhner K; Döhner H; González-Menéndez I; Quintanilla-Fend L; Herold T; Jeremias I; Feuring-Buske M; Buske C; Rawat VPS
    Leukemia; 2021 Feb; 35(2):389-403. PubMed ID: 32409690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrospinning of dexamethasone/cyclodextrin inclusion complex polymer fibers for dental pulp therapy.
    Daghrery A; Aytac Z; Dubey N; Mei L; Schwendeman A; Bottino MC
    Colloids Surf B Biointerfaces; 2020 Jul; 191():111011. PubMed ID: 32334136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer.
    Li J; Yao QY; Xue JS; Wang LJ; Yuan Y; Tian XY; Su H; Wang SY; Chen WJ; Lu W; Zhou TY
    Acta Pharmacol Sin; 2017 Sep; 38(9):1282-1296. PubMed ID: 28649130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.
    Zou Y; Mei D; Yuan J; Han J; Xu J; Sun N; He H; Yang C; Zhao L
    Int J Nanomedicine; 2021; 16():1127-1141. PubMed ID: 33603372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
    Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
    Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
    Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
    Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.
    Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Nishida J; Kanda Y
    Ann Hematol; 2016 Jan; 95(1):87-92. PubMed ID: 26391025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.